HM 97594
Alternative Names: HM-97594Latest Information Update: 28 Jan 2024
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; EZH1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in South Korea (PO)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Solid-tumours in South Korea (PO)
- 09 Dec 2019 HM 97594 is available for licensing as of 09 Dec 2019. http://www.hanmipharm.com/ehanmi/handler/Home-Start